{
    "title": "AstraZeneca cancer drug trial prompts investors to take options cover",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4644484/AstraZeneca-cancer-drug-trial-prompts-investors-options-cover.html",
    "date": "2017-06-27",
    "keywords": [
        "trial",
        "cancer",
        "market",
        "lung",
        "combination",
        "drug",
        "durvalumab",
        "june",
        "astrazeneca",
        "treatment",
        "group",
        "immunotherapy",
        "july",
        "week",
        "call",
        "right",
        "price",
        "future",
        "date",
        "hirschler",
        "saqib",
        "iqbal",
        "york",
        "drugmaker",
        "day",
        "slice",
        "tremelimumab",
        "outcome",
        "nature",
        "experiment",
        "ability",
        "care",
        "race",
        "opportunity",
        "co",
        "light",
        "keytruda",
        "chemotherapy",
        "roche",
        "news",
        "end",
        "companys",
        "trade",
        "impact",
        "put",
        "option",
        "set",
        "analysis",
        "percent",
        "direction",
        "focus",
        "executive",
        "soriot",
        "oncology",
        "cholesterol",
        "fighter",
        "crestor",
        "nexium",
        "tuesday",
        "clarity",
        "headline",
        "time",
        "example",
        "congress",
        "year",
        "helps",
        "protein",
        "pdl1",
        "business",
        "boost",
        "month",
        "progression",
        "disease",
        "goodman"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}